Viking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase. VKTX's ...

VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy ...

We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX.

Viking Therapeutics (NASDAQ:VKTX), often touted as an attractive obesity play, shed more than a third of its value this week after mid-stage trial data for its oral obesity candidate VK2735 ...

After a dismal 2019, biotech company Viking Therapeutics (NASDAQ:VKTX) has recovered a portion of its value. The stock has risen by 17.8% compared to its November 1 price to $7.92 and a market cap of ...

Andrew Kessel was a breaking news writer for Investopedia until October 2025. He previously covered markets for Proactive Investors, with a focus on small-cap stocks in fintech, healthcare, mining, ...